Physician profile
Fernando Diaz
NPI 1902333545
$5,738.92
in general payments reported to CMS, 2019-2025
40 companies · $5,678 in 2025
The $5,678 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $61.41 · 2025: $5,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Travel and Lodging: $908 · Education: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,270.98 |
| Travel and Lodging | $907.89 |
| Education | $560.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,487.69 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Daiichi Sankyo INC. | $302.01 | 2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $248.21 | 2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $224.04 | 2025 | Xpovio |
| Abbvie INC. | $198.20 | 2025 | |
| Janssen Biotech, INC. | $161.62 | 2025 | Rybrevant, Carvykti, Darzalex |
| Lilly USA, LLC | $140.21 | 2025 | Jaypirca, Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $139.44 | 2025 | |
| Pharmacosmos Therapeutics INC. | $135.33 | 2025 | Cosela, Monoferric |
| Incyte Corporation | $134.57 | 2025 | Monjuvi, Monjuvi |
| Medtronic, INC. | $129.59 | 2025 | Osteocool Rf Ablation System |
| Exelixis INC. | $124.40 | 2025 | Cabometyx |
| Seagen INC. | $99.95 | 2025 | |
| Galvanize Therapeutics, INC | $91.06 | 2025 | Aliya System |
| Pfizer INC. | $85.87 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $83.67 | 2025 | Opdualag, Opdivo |
| Genzyme Corporation | $82.53 | 2025 | |
| Celgene Corporation | $76.69 | 2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $70.69 | 2025 | Tecentriq, Itovebi |
| Merck Sharp & Dohme LLC | $66.53 | 2025 | Keytruda |
| Jazz Pharmaceuticals INC. | $65.12 | 2025 | |
| Integra Lifesciences Corporation | $64.02 | 2025 | Duraseal Exact Spinal Sealant System, Codman Certas, Codman Hakim |
| Caris Mpi, INC. | $52.42 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $38.71 | 2025 | |
| Geron Corporation | $37.12 | 2025 | Rytelo |
| Ipsen Biopharmaceuticals, INC | $36.98 | 2025 | Onivyde |
| Ferring Pharmaceuticals INC. | $36.76 | 2025 | Adstiladrin |
| Aveo Pharmaceuticals, INC. | $36.43 | 2024-2025 | |
| Taiho Oncology, INC. | $35.47 | 2025 | |
| Genmab U.S., INC. | $29.18 | 2025 | Epkinly |
| Tempus Ai, INC | $26.96 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.99 | 2025 | Fruzaqla |
| Eisai INC. | $24.23 | 2025 | |
| Array Biopharma INC | $23.68 | 2025 | Mektovi, Tukysa, Braftovi |
| Stemline Therapeutics INC. | $23.24 | 2025 | Orserdu |
| Syndax Pharmaceuticals, INC. | $22.70 | 2025 | |
| Deciphera Pharmaceuticals INC. | $22.52 | 2025 | Qinlock, Tgct |
| Agios Pharmaceuticals, INC. | $20.12 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $18.02 | 2024 | Libtayo |
| Glaxosmithkline, LLC. | $17.95 | 2025 | Blenrep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.